

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 22nd October, 2018

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id : 506365

Subject : **SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter ended 30th September, 2018 as under -


1.	Regulation 33	Un-audited Quarterly Financial Results along with Statement of Assets And Liabilities for the Quarter ended 30/09/2018 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 22/10/2018

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)





LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30th September, 2018**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

NO: C/02/1018
Dated: 22/10/2018
Place: MUMBAI

For M/s VMD & CO.
Chartered Accountants.
FRN: 125002W


CA AMIT GANPULE
PARTNER
MRN: 114222



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2018

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Half Year Ended		Year Ended
		30th Sept 2018	30th June 2018	30th Sept 2017	30th Sept 2018	30th Sept 2017	31st March 2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations						-
II	Other Income	1,299	1,240	2,341	2,539	3,718	11,055
III	Total Revenue (I + II)	1,299	1,240	2,341	2,539	3,718	11,055
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	506	563	520	1,069	764	1,564
	(5) Depreciation and Amortisation Expenses	-	-	-	-	-	35
	(6) Other Expenses (Any Item exceeding 10% of the Total Expenses relating to continuing Operations to be shown separately)	533	601	159	1,229	324	417
	i) Professional Charges	188	-	8	294	75	991
	ii) Share Registry Expenses	-	-	22	-	37	100
	iii) Annual Listing Fees	-	310	17	310	315	315
	iv) Travelling Expenses	-	268	-	268	-	-
	v) Postal Charges	201	-	-	-	-	-
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	1,428	1,742	726	3,170	1,515	3,422
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	(129)	(502)	1,616	(631)	2,204	7,633
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	(129)	(502)	1,616	(631)	2,204	7,633
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	(129)	(502)	1,616	(631)	2,204	7,633
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	5,177	1,450
	(2) Tax Adjustment Previous Year	-	-	-	-	-	5,177
	(3) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	(129)	(502)	1,616	(631)	(2,974)	1,006
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	(129)	(502)	1,616	(631)	(2,974)	1,006
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	(129)	(502)	1,616	(631)	(2,974)	1,006
XVIII	Earnings per Share :						
	(1) Basic	(0.09)	(0.33)	1.08	(0.42)	(1.98)	0.67
	(2) Diluted						

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.

- 2 The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2018 have been reviewed by the Audit Committee in their Meeting held on 22.10.2018 and approved by the Board of Directors of its Meeting held on 22.10.2018. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)



Place : Mumbai

Date : 22nd October, 2018

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 • Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 30TH SEPTEMBER, 2018

(Rupees in Thousands)

Sr. No.	PARTICULARS	As at 30.09.2018 Unaudited	As at 31.03.2018 Audited
1	ASSETS		
1	Non-Current Assets		
	(A) Fixed Assets		
	Tangible Assets	77	21
	(B) Financial Assets		
	(i) Investment	187	187
	(ii) Long Term Loans	16,884	16,884
2	Current Assets		
	(i) Cash & Cash Equivalents	1,459	76,637
	(ii) Short Term Loans	352	8,835
	(iii) Loan & Advances	625	-
	(iv) Receivable	2,213	-
	(v) Deposits (Fixed Deposits)	80,000	-
	<i>Sub Total</i>	84,649	85,472
	GRAND TOTAL	101,798	102,564
2	EQUITY AND LIABILITIES		
	EQUITY		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	85,601	86,232
	<i>Sub Total</i>	100,601	101,232
1	Non-Current Liabilities		
	(A) Financial Liabilities		
	(i) Long Term Borrowings	1,197	1,197
2	Current Liabilities		
	(i) Short-Term Borrowings	-	-
	(ii) Other Current Liabilities	-	69
	(iii) Short-Term Provisions	-	66
	<i>Sub Total</i>	-	135
	GRAND TOTAL	101,798	102,564

FOR CHEMO PHARMA LABORATORIES LIMITED

Ashok Somani
 ASHOK SOMANI
 DIRECTOR
 (DIN NO. - 03063364)



Place : Mumbai

Date : 22nd October, 2018

CHEMO PHARMA LABORATORIES LIMITED


Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDLONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2018

(Rs. In Thousand)

PARTICULARS	STANDLONE	
	UNAUDITED QUARTER ENDED 30.09.2018	UNAUDITED HALF YEAR ENDED 30.09.2018
Reconciliation of Profit After Tax as reported earlier:		
Net Profit / (Loss) for the Period (as per AS)	(129.00)	(631.00)
Benefit / (Charge):	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-
Impact of Fair Valuation of Financial Instruments	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-
Impact of Adjustment of Deferred Tax	-	-
Net Profit / (Loss) for the Period (as per AS)	(129.00)	(631.00)

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)



Mumbai, 22nd October, 2018